Nested combination tests with a time‐to‐event endpoint using a short‐term endpoint for design adaptations
暂无分享,去创建一个
Martin Posch | Gernot Wassmer | Franz König | Silke Jörgens | G. Wassmer | M. Posch | F. König | S. Jörgens
[1] E. Bluhmki,et al. A statistical model for the dependence between progression‐free survival and overall survival , 2009, Statistics in medicine.
[2] H. Schäfer,et al. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections , 2001, Statistics in medicine.
[3] K. Gabriel,et al. On closed testing procedures with special reference to ordered analysis of variance , 1976 .
[4] Martin Posch,et al. Adaptive designs for subpopulation analysis optimizing utility functions , 2014, Biometrical journal. Biometrische Zeitschrift.
[5] P. Bauer,et al. Modification of the sample size and the schedule of interim analyses in survival trials based on data inspections by H. Schäfer and H.‐H. Müller, Statistics in Medicine 2001; 20: 3741–3751 , 2004, Statistics in medicine.
[6] Helmut Schäfer,et al. Interim Design Modifications in Time-to-Event Studies , 2012 .
[7] Hui Quan,et al. An Adaptive Timeline Determination of Survival Trials , 2018, Statistics in Biopharmaceutical Research.
[8] B. Freidlin,et al. Sample size adjustment designs with time-to-event outcomes: A caution , 2017, Clinical trials.
[9] R. Uozumi,et al. Interim decision-making strategies in adaptive designs for population selection using time-to-event endpoints , 2017, Journal of biopharmaceutical statistics.
[10] Gernot Wassmer,et al. Group Sequential and Confirmatory Adaptive Designs in Clinical Trials , 2016 .
[11] T. Friede,et al. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review , 2016, Journal of biopharmaceutical statistics.
[12] Cyrus Mehta,et al. Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints , 2014, Statistics in medicine.
[13] L Di Scala,et al. Time‐to‐event analysis with treatment arm selection at interim , 2011, Statistics in medicine.
[14] C. Jennison,et al. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints † , 2011, Pharmaceutical statistics.
[15] R. Prentice. Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.
[16] M Kieser,et al. Combining different phases in the development of medical treatments within a single trial. , 1999, Statistics in medicine.
[17] Thomas R Fleming,et al. Issues in using progression-free survival when evaluating oncology products. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] D. DeMets,et al. Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.
[19] Frank Bretz,et al. Twenty‐five years of confirmatory adaptive designs: opportunities and pitfalls , 2015, Statistics in medicine.
[20] Martin Posch,et al. Optimized adaptive enrichment designs , 2017, Statistical methods in medical research.
[21] Gernot Wassmer,et al. Planning and Analyzing Adaptive Group Sequential Survival Trials , 2006, Biometrical journal. Biometrische Zeitschrift.
[22] Martin Posch,et al. Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials , 2016, PloS one.
[23] Martin Posch,et al. Testing and estimation in flexible group sequential designs with adaptive treatment selection , 2005, Statistics in medicine.
[24] Tim Friede,et al. Adaptive Designs for Confirmatory Clinical Trials with Subgroup Selection , 2014, Journal of biopharmaceutical statistics.
[25] H. Schäfer,et al. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches , 2001, Biometrics.
[26] A. Tsiatis,et al. Approximately optimal one-parameter boundaries for group sequential trials. , 1987, Biometrics.
[27] P. Bauer,et al. Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.
[28] T Friede,et al. Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: An application in multiple sclerosis , 2011, Statistics in medicine.
[29] Kaspar Rufibach,et al. Comparison of different clinical development plans for confirmatory subpopulation selection. , 2016, Contemporary clinical trials.
[30] Nigel Stallard,et al. A confirmatory seamless phase II/III clinical trial design incorporating short‐term endpoint information , 2010, Statistics in medicine.
[31] C. Weir,et al. Statistical evaluation of biomarkers as surrogate endpoints: a literature review , 2006, Statistics in medicine.
[32] A. Azuero. A note on the magnitude of hazard ratios , 2016, Cancer.
[33] T. Fleming,et al. Biomarkers and surrogate endpoints in clinical trials , 2012, Statistics in medicine.
[34] G. Hommel. Adaptive Modifications of Hypotheses After an Interim Analysis , 2001 .
[35] David L. DeMets,et al. Design and analysis of group sequential tests based on the type I error spending rate function , 1987 .
[36] M. Kendall,et al. Rank and product-moment correlation. , 1949, Biometrika.
[37] Georg Gutjahr,et al. Adaptive seamless designs with interim treatment selection: a case study in oncology , 2015, Statistics in medicine.